🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

647 results for “Les” Clear

  1. Mipomersen sodium

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  2. Multi-centre, Open-label Trial to Assess the SaFety, Pharmacodynamics, Efficacy and Pharmacokinetics of PegunigaLsidase Alfa in Patients from 2 Years to Less Than 18 Years of Age with Confirmed FabrY Disease (FLY)

    Chiesi Farmaceutici S.p.A

    Fabry's disease

    phase 3 other active

    1 trial

  3. Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, Lynparza 100 mg film-coated tablets, Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Imfinzi 50 mg/ml, Lynparza 100 mg, Lynparza 150 mg, Myfenax 250 mg hard capsules, Flixabi 100 mg p

    AstraZeneca AB

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  4. N-Acetyl-L-Leucine, granules for suspension

    Intrabio Ireland Limited

    CACNA1A Disorders

    phase 3 small molecule active

    1 trial

  5. NBI-74788, Crinecerfont placebo for oral capsules

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  6. NEORAL® Soft Gelatin Capsules 100mg, Methotrexate 2.5 mg Tablets, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Prednisolone 5mg Tablets, Azathioprine Tablets 50mg Oprisine, Privigen 100 mg/ml solution for infusion, Soliris 300 mg concentrate for solution for infusion, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 50mg, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 10mg, Methotrexate 2.5 mg Tablets, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 25mg, K

    Kyverna Therapeutics

    Generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  7. Namuscla 167 mg hard capsules, Mexiletine granules for prolonged-release oral suspension 167 mg, Mexiletine granules for prolonged-release oral suspension 500 mg, Mexiletine granules for prolonged-release oral suspension 333 mg

    Lupin Europe GmbH

    Non-Dystrophic Myotonias (NDM)

    phase 3 small molecule active

    1 trial

  8. Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, Imnovid 2 mg hard capsules, Privigen 100 mg/ml solution for infusion, ELRANATAMAB, Imnovid 3 mg hard capsules

    Pfizer Australia Pty Ltd

    MULTIPLE MYELOMA

    phase 3 small molecule active

    1 trial

  9. Niraparib Placebo Capsules, Niraparib Placebo Tablets, G5W (5% glucose in water), JEMPERLI 500 mg concentrate for solution for infusion

    TESARO Bio Netherlands B.V.

    Recurrent or primary advanced (Stage III or IV) endometrial cancer

    phase 3 small molecule active

    1 trial

  10. OCTAGAM 10 %, Lösung zur intravenösen Infusion, Cytarabine 20 mg/ml Solution for Injection/Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Prednisolone 5mg Tablets, Methotrexate 10 mg Tablets, Vinblastine Sulfate 1 mg/ml Solution for Injection or Infusion, Melphalan 50 mg Powder and Solvent for Solution for Injection/Infusion, INDOMETACIN CAPSULES BP 25mg, LEMTRADA 12 mg concentrate for solution for infusion, Mercaptopurine Silver Pharma 50 mg tablets, LITAK 2 mg

    The George Institute

    Langerhans Cell Histiocytosis

    phase 3 small molecule active

    1 trial

  11. ONDANSETRON ZYDUS 8 mg, comprimé orodispersible, Jakavi 5 mg tablets, EMEND 125 mg+80 mg hard capsules, Jakavi 15 mg tablets, Jakavi 20 mg tablets, PALONOSETRON, NETUPITANT, Akynzeo 300 mg/0.5 mg hard capsules, Selinexor placebo for 20 mg tablets formulated for oral administration., Jakavi 10 mg tablets, SELINEXOR, ONDANSETRON

    Karyopharm Therapeutics Inc

    Treatment naïve patients with MF

    phase 3 small molecule active

    1 trial

  12. OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, LENVIMA 10 mg hard capsules, AXITINIB SANDOZ 5 mg, comprimé pelliculé, CABOMETYX 40 mg film-coated tablets

    The George Institute

    Metastatic renal cell carcinoma (mRCC)

    phase 3 small molecule active

    1 trial

  13. Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, G

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

    phase 3 small molecule active

    1 trial

  14. Oxycodone/Naltrexone Capsules

    ELITE PHARMACEUTICALS INC /NV/

    Withdrawal Symptoms

    phase 3 small molecule completed

    1 trial

  15. PEGASPARGASE

    Pari Pharma GmbH

    This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newly diagnosed with standard/medium-risk ALL

    phase 3 small molecule active

    1 trial

  16. PL2200 Aspirin Capsules

    Protalix BioTherapeutics

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials

  17. PREDNISOLONE , Verzenios 50 mg film-coated tablets, Placebo to match LY2835219 (Abemaciclib) Tablets, Placebo to match LY2835219 (Abemaciclib) Capsules, PREDNISONE , ABIRATERONE

    Eli Lilly Co.

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  18. Paclitaxel 6mg/ml Concentrate for Solution for Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Tamoxifen 20 mg Tablets, Epirubicin 2 mg/ml Solution for Injection, Endoxana Injection 500 mg Powder for Solution for Injection, Anastrozole 1 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion

    Ningbo Cancer Hospital

    Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less

    phase 3 small molecule active

    1 trial

  19. Palazestrant matching placebo tablets and Letrozole matching placebo capsules, Palazestrant, RIBOCICLIB, Palazestrant, -, LETROZOLE , Palazestrant

    Olema Pharmaceuticals

    ER+, HER2- Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  20. Placebo

    Regeneron UK Limited

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  21. Placebo

    Milestone Pharmaceuticals

    Atrial Fibrillation

    phase 3 small molecule active

    1 trial

  22. Placebo (for alirocumab)

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule completed

    5 trials

  23. Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg), TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Hypertension Associated with Interstitial Lung Disease

    phase 3 small molecule active

    1 trial

  24. Placebo (inhalation powder capsules) containing 1 of 4 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg or 640 µg ), TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Hypertension Associated with Interstitial Lung Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources